STOCK TITAN

Wellington group discloses over 5% Cytokinetics (CYTK) holding for clients

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Cytokinetics, Incorporated received an updated ownership report from Wellington Management Group LLP and related entities, filing Amendment No. 2 to a Schedule 13G for its Common Stock (CUSIP 23282W605) as of 06/30/2026.

Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively report 7,116,724 shares of Cytokinetics common stock as beneficially owned, representing 5.12% of the class. These entities report 0 shares with sole voting or dispositive power, 6,231,890 shares with shared voting power, and 7,116,724 shares with shared dispositive power. The shares are owned of record by clients of various Wellington investment advisers, and no single client is reported to hold more than five percent of the class.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 7,116,724.00 shares Beneficial ownership of Cytokinetics common stock reported by Wellington entities
Percent of class 5.12 % Reported percentage of Cytokinetics common stock outstanding as of 06/30/2026
Shared voting power 6,231,890.00 shares Shares of Cytokinetics common stock with shared power to vote or direct the vote
Shared dispositive power 7,116,724.00 shares Shares of Cytokinetics common stock with shared power to dispose or direct disposition
Reporting date 06/30/2026 Date as of which the Schedule 13G/A ownership information is provided
beneficially owned financial
"Item 4. | Ownership (a) | Amount beneficially owned: See the responses to Item 9"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"6 | Shared Voting Power 6,231,890.00 7 | Sole Dispositive Power"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"8 | Shared Dispositive Power 7,116,724.00 9 7,116,724.00"
parent holding company financial
"The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company"
investment advisers financial
"One or more of the following investment advisers (the "Wellington Investment Advisers")"

FAQ

What percentage of Cytokinetics (CYTK) does Wellington report owning?

Wellington entities report beneficial ownership of 5.12% of Cytokinetics’ common stock. This corresponds to 7,116,724 shares as of June 30, 2026, held on behalf of clients of various Wellington investment advisers.

How many Cytokinetics (CYTK) shares does Wellington have voting power over?

Wellington reports 6,231,890 Cytokinetics shares with shared voting power and 0 shares with sole voting power. Voting authority is exercised collectively through Wellington-managed investment advisory relationships rather than direct ownership by Wellington itself.

How many Cytokinetics (CYTK) shares can Wellington dispose of?

Wellington reports 7,116,724 Cytokinetics shares with shared dispositive power and 0 with sole dispositive power. These shares are owned of record by clients of Wellington investment advisers, which can direct sales or other dispositions under advisory authority.

Who actually owns the Cytokinetics (CYTK) shares reported by Wellington?

The 7,116,724 Cytokinetics shares are owned of record by clients of the Wellington investment advisers. Wellington notes those clients receive dividends and sale proceeds, and no individual client is known to hold more than 5% of the class.

Which Wellington entities are reporting the Cytokinetics (CYTK) stake?

The reporting persons are Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP. They file as parent holding and control entities over various Wellington investment advisers that manage the Cytokinetics position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





23282W605

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026
Wellington Group Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026
Wellington Investment Advisors Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026